The Goldman Sachs Group Lowers Cellectis (NASDAQ:CLLS) Price Target to $2.00

Cellectis (NASDAQ:CLLSGet Rating) had its price target reduced by stock analysts at The Goldman Sachs Group from $3.00 to $2.00 in a report issued on Tuesday, Stock Target Advisor reports. The brokerage presently has a “sell” rating on the biotechnology company’s stock. The Goldman Sachs Group’s target price suggests a potential downside of 43.98% from the company’s current price.

Several other equities analysts have also weighed in on the company. Barclays cut their target price on Cellectis from $9.00 to $7.00 in a research note on Friday, May 13th. StockNews.com raised Cellectis from a “sell” rating to a “hold” rating in a research report on Wednesday, May 18th. Zacks Investment Research lowered Cellectis from a “buy” rating to a “hold” rating in a research report on Monday. Finally, Robert W. Baird upgraded Cellectis from a “neutral” rating to an “outperform” rating and set a $10.00 price target for the company in a research note on Wednesday, May 18th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $15.25.

Shares of CLLS stock traded down $0.12 during trading hours on Tuesday, reaching $3.57. 1,707 shares of the company’s stock were exchanged, compared to its average volume of 255,300. The business has a fifty day moving average price of $3.99 and a 200-day moving average price of $6.03. The company has a quick ratio of 3.73, a current ratio of 3.73 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $162.40 million, a P/E ratio of -1.21 and a beta of 2.24. Cellectis has a fifty-two week low of $2.85 and a fifty-two week high of $16.53.

Cellectis (NASDAQ:CLLSGet Rating) last announced its earnings results on Thursday, March 3rd. The biotechnology company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($1.05) by $0.50. The company had revenue of $13.66 million for the quarter, compared to analysts’ expectations of $12.30 million. Cellectis had a negative return on equity of 53.48% and a negative net margin of 312.64%. During the same quarter in the prior year, the business earned ($0.95) earnings per share. As a group, research analysts expect that Cellectis will post -2.19 EPS for the current fiscal year.

A number of hedge funds have recently modified their holdings of the stock. Moors & Cabot Inc. bought a new stake in shares of Cellectis in the 3rd quarter valued at about $287,000. US Bancorp DE grew its position in shares of Cellectis by 94.0% in the 3rd quarter. US Bancorp DE now owns 2,332 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 1,130 shares during the last quarter. Deutsche Bank AG bought a new stake in shares of Cellectis in the 3rd quarter valued at about $42,000. Signaturefd LLC grew its position in shares of Cellectis by 1,066.0% in the 4th quarter. Signaturefd LLC now owns 3,801 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 3,475 shares during the last quarter. Finally, Advisor Group Holdings Inc. grew its position in shares of Cellectis by 73.9% in the 4th quarter. Advisor Group Holdings Inc. now owns 4,950 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 2,103 shares during the last quarter. Institutional investors and hedge funds own 40.55% of the company’s stock.

Cellectis Company Profile (Get Rating)

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia.

See Also

Stock Target Advisor logo

Analyst Recommendations for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.